Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy

Clin Lung Cancer. 2019 Nov;20(6):e597-e600. doi: 10.1016/j.cllc.2019.08.002. Epub 2019 Aug 26.
No abstract available

Keywords: Circulating tumor DNA; Clonal evolution; EGFR mutation; Liquid biopsy; Resistance mutations.

Publication types

  • Case Reports

MeSH terms

  • Acrylamides / therapeutic use*
  • Aniline Compounds / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Blood Circulation
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Circulating Tumor DNA / analysis
  • DNA Mutational Analysis
  • Drug Resistance, Neoplasm / genetics
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / genetics
  • Humans
  • Liquid Biopsy
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Protein Kinase Inhibitors / therapeutic use*

Substances

  • Acrylamides
  • Aniline Compounds
  • Antineoplastic Agents
  • Circulating Tumor DNA
  • Protein Kinase Inhibitors
  • osimertinib
  • EGFR protein, human
  • ErbB Receptors